Tokyo, Japan, April 27, 2017 - Astellas Pharma Inc. (TSE: 4503; President and CEO: Yoshihiko Hatanaka, hereinafter called 'the Company') announced that at the meeting of the Board of Directors held today, a resolution was adopted that the Company will cancel its treasury shares, pursuant to Article 178 of the Companies Act.

Particulars

1. Class of shares to be cancelled Common stock of the Company

2. Number of shares to be cancelled 85 million shares

(Representing 3.95% of issued shares prior to

cancellation)

3. Cancellation date May 31, 2017

(Reference)

  1. Following cancellation, the Company will have 2,068,823,175 issued shares.
  2. Total number of the Company's treasury shares after cancellation will be 3,817,886.

(Expected numbers of shares described above 1 and 2 were calculated on the basis of the issued shares and the Company's treasury shares as of March 31, 2017, respectively.)

###

Astellas Pharma Inc. published this content on 27 April 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 27 April 2017 03:22:10 UTC.

Original documenthttps://www.astellas.com/en/corporate/news/detail/astellas-announces-cancellatio-9.html

Public permalinkhttp://www.publicnow.com/view/171F76CEA6C0642E1D3D547B090960872ED2DC1E